Trevi Therapeutics, Inc. (TRVI)
NASDAQ: TRVI · IEX Real-Time Price · USD
2.780
+0.120 (4.51%)
At close: Jul 19, 2024, 4:00 PM
2.760
-0.020 (-0.72%)
Pre-market: Jul 20, 2024, 9:28 AM EDT
Trevi Therapeutics Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Trevi Therapeutics stock have an average target of 8.00, with a low estimate of 7.00 and a high estimate of 9.00. The average target predicts an increase of 187.77% from the current stock price of 2.78.
Analyst Consensus: Strong Buy
* Price targets were last updated on Jun 13, 2024.
Analyst Ratings
The average analyst rating for TRVI stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
---|---|---|---|---|---|---|
Strong Buy | 3 | 2 | 2 | 1 | 2 | 2 |
Buy | 1 | 1 | 1 | 1 | 1 | 1 |
Hold | 0 | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 4 | 3 | 3 | 2 | 3 | 3 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Rodman & Renshaw | Rodman & Renshaw | Strong Buy Initiates $7 | Strong Buy | Initiates | $7 | +151.80% | Jun 13, 2024 |
Needham | Needham | Strong Buy Reiterates $8 | Strong Buy | Reiterates | $8 | +187.77% | May 8, 2024 |
Needham | Needham | Strong Buy Reiterates $8 | Strong Buy | Reiterates | $8 | +187.77% | Apr 9, 2024 |
Needham | Needham | Strong Buy Reiterates $8 | Strong Buy | Reiterates | $8 | +187.77% | Mar 21, 2024 |
Oppenheimer | Oppenheimer | Buy Maintains $9 | Buy | Maintains | $9 | +223.74% | Mar 21, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-0.44
from -0.29
EPS Next Year
-0.48
from -0.44
Revenue Forecast
Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | n/a | n/a | n/a | 30.0M | 125.1M |
Avg | n/a | n/a | n/a | 12.1M | 91.9M |
Low | n/a | n/a | n/a | 4.2M | 43.9M |
Revenue Growth
Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | - | - | - | - | 930.1% |
Avg | - | - | - | - | 656.8% |
Low | - | - | - | - | 261.4% |
EPS Forecast
EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | -0.39 | -0.40 | -0.53 | -0.37 | 0.14 |
Avg | -0.44 | -0.48 | -0.69 | -0.67 | -0.16 |
Low | -0.45 | -0.61 | -0.86 | -1.10 | -0.68 |
EPS Growth
EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | - | - | - | - | - |
Avg | - | - | - | - | - |
Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.